27 August 2020

Much research has been done on the effectiveness and safety of systemic antipsoriasis therapies in general, but the effectiveness in specifically older adults psoriasis patients has never been systematically assessed. 

Led by Satish Lubeek of the Department of Dermatology (photo), physician-researchers Marieke van Winden and Lara van der Schoot - together with other researchers - have conducted research into the effectiveness and safety of systemic anti-psoriasis therapies in patients over 65 years of age.

Findings

It seems that the effectiveness of treatment with acitretin, etanercept, adalimumab and secukinumab is not affected by advanced age. Studies of other systemic anti-psoriasis drugs have not made age group comparisons. Older age was significantly associated with impairment of renal function in users of ciclosporin and lymphopenia in users of fumaric acid. Infections were the most frequently reported side effect in patients over 65 years of age using biologics; no significant association with age was found.

Conclusions and relevance

Based on the very limited relevant studies available, age alone should not be a limiting factor in the treatment of psoriasis. Awareness of other medical conditions and concomitant medication use is very important in older adults, as well as possible dosage adjustments and frequent laboratory and clinical monitoring.
  
More research from daily practice, as well as (sub)analyses of prospective cohort studies on the effectiveness and safety of systemic therapies in older adults, are crucial for optimizing personalized, effective and safe anti-psoriasis treatments in this growing patient group.

The research was recently published in the scientific medical journal Journal of the American Medical Association: Jama Dermatology. It is also discussed in the corresponding editorial.

Related news items


Large NWA ORC grant awarded for national skin research: Next Generation ImmunoDermatology

23 March 2022 Research for better treatment methods for chronic skin diseases. read more

ZonMw funding for PSIDER program

14 July 2021 Michiel Vermeulen, Klaas Mulder and Nael Nadif Kasri receive funding from ZonMw for a collaborative project to develop a stem cell based model to study early human embryogenesis. read more

2.5 million Euros for cancer research into ovarian cancer and immunotherapy

15 April 2021 The Radboudumc receives 2.5 million Euros from the Dutch Cancer Society (KWF) for three studies to ensure oncological progress during COVID-19 period. read more

Tight controlled dose reduction of biologics in psoriasis patients

7 May 2020 Published in JAMA Dermatology, RIHS researcher Selma Atalay and colleagues investigated in a randomized controlled trial a tight controlled dose reduction strategy of the biologics adalimumab, etanercept and ustekinumab in psoriasis patients. read more

Guiding the surgeon real-time tumor visualization during surgery

26 February 2020 Incomplete excision of tumor tissue negatively affects the prognosis of the patient. RIHS researcher Mark Rijpkema and colleagues are working on the development of new dual-labeled tracers and currently are implementing this into the clinic. read more

First BeNeFit funding granted for psoriasis

17 January 2020 RIHS researchers Elke de Jong and Juul van den Reek of Dermatology Radboudumc and Dermatology Ghent received a grant of 1.6 million euros for investigating dose reduction of the newest biologics for psoriasis. read more